User:3nineComms/sandbox

Medical Technology Group (MTG)
The Medical Technology Group (MTG) is a not for profit organisation in the United Kingdom comprising patient groups, research charities and medical device manufacturers. Its stated aim is to "work together to improve patient access to effective medical technologies". The Group launched in 2000.

Membership
Current members of the MTG are:


 * ABHI
 * AdvaMed
 * AntiCoagulation Europe
 * ARMA
 * Arrhythmia Alliance
 * Arthritis Care
 * Atrial Fibrillation Association
 * BD
 * Bladder and Bowel Foundation
 * Boston Scientific
 * British Cardiac Patients Association
 * C R Bard
 * Cardiomyopathy Association
 * Diabetes UK
 * Eucomed
 * FABLE
 * FEmISA
 * Heart Research UK
 * ICD Group
 * INPUT Patient Advocacy
 * International Alliance of Patients' Organisations
 * JDRF
 * Johnson & Johnson
 * Lindsay Leg Club
 * Medtronic
 * National Rheumatoid Arthritis Society
 * Pelvic Pain Support Network
 * Roche Diagnostics
 * SADS UK
 * St Jude Medical
 * STARS
 * Stryker
 * The Circulation Foundation
 * The Patients Association
 * Transplant Support Network

Hip and Knee Surgery: Combating Patient Lotteries
In November 2013, the MTG published a report into waiting times for knee and hip replacements on the National Health Service. The report: Hip and Knee Surgery: Combating Patient Lotteries reviewed ten years of government data on knee and hip replacement, and data from Freedom of Information requests to acute NHS hospital trusts in England. The report suggested that patient experiences vary significantly according to the financial calendar.

Work Foundation report
In November 2011, The Work Foundation published a report, Adding Value: The Economic and Societal Benefits of Medical Technology, funded by a research grant from the MTG. The report, which was launched in the House of Commons, identified three key areas of benefits from medical technologies:


 * Improvements in health care (quality, efficiency and the empowerment of patients);
 * Improving quality of life and independent living (reducing fears and anxiety, increasing flexibility, and reducing the need for informal care and the burden on informal caregivers);
 * Labour market participation and productivity (increasing labour market participation, retaining skills and improving productivity).

Uterine Artery/Fibroid Embolisation (UFE)
In 2011 the MTG and patient support group FEmISA published a report The provision of and access to Uterine Artery/Fibroid, a less invasive treatment for fibroids for women. The report, which was welcomed by the British Society of Interventional Radiologists, highlighted a lack of coherent commissioning in England, despite National Institute for Health and Care Excellence clinical guidelines recommending UFE as a first line treatment for symptomatic fibroids.

Insulin Pump Provision
In 2010 the MTG made a Freedom of Information request to Primary Care Trusts in England on the provision of insulin pumps to patients with Type 1 diabetes. It found the average to be 3.9 per cent compared to the 12 per cent benchmark recommended by the National Institute for Health and Clinical Excellence. The findings were the subject of an Early Day Motion tabled by Adrian Sanders MP on December 9, 2010.

Making the Economic Case for Medical Technology
In 2004, the MTG's report Making the Economic Case for Medical Technology suggested that increasing the provision of medical technology can "help patients better manage their conditions" and lead a "longer and relatively healthy life". It also suggested that by making greater use of technology there are cost benefits for the the National Health Service. The report was the subject of an Early Day Motion tabled by Ian Gibson MP. The motion was signed by 30 Members of Parliament.

Organisation
The MTG is currently chaired by Barbara Harpham, National Director of Heart Research UK. She has been quoted as saying that the UK lags behind other European countries in the take-up of medical technology.